The United States and Europe have begun to vaccinate the new crown pneumonia vaccine on a large scale. Although domestic vaccines in China have received orders from the Hong Kong Special Administrative Region and many countries and regions, they have not yet been officially launched. The large-scale vaccination will have to wait until 2021. Experts from China’s National Health Commission said that China’s vaccine research and development is in the “first phalanx” in the world, but it will not compete to be the first. Xinhua News Agency pointed out that China does not actually have the conditions for conducting Phase III clinical trials of the new crown vaccine.
Xinhua News Agency reported that China currently has 5 technical routes and a total of 15 new crown vaccines entering clinical trials. Vaccines that have entered phase III clinical trials include: 2 inactivated vaccines from Sinopharm Sino Biotech, 1 inactivated vaccine from Beijing Kexing Zhongwei Company, adenovirus vector vaccine jointly developed by the Military Medical Research Institute and Kangsino Company, and Institute of Microbiology, Chinese Academy of Sciences A recombinant protein vaccine jointly developed with Zhifei Biological Company.
Zheng Zhongwei, head of the Vaccine R&D Special Team of the Joint Prevention and Control Mechanism Research Team of the State Council, and director of the National Health Commission’s Medical Science and Technology Development Research Center, said that China is now preparing for mass production of vaccines. He described: “China’s vaccine research and development has entered the sprint stage. We are in the world’s first phalanx, but we are not rushing for the first place.”
Why are China’s vaccine data not coming out?Because the efficiency is calculated like this
According to the report, since the new crown pneumonia epidemic is under control in China, the domestic conditions for phase III clinical trials are no longer available. Therefore, the above-mentioned phase III clinical trials are mainly conducted overseas, and they also face some difficulties and challenges.
Zheng Zhongwei also explained that China has five new coronavirus vaccines in phase III clinical trials, and the number is among the highest in the world, and evaluation of a vaccine requires multiple comprehensive indicators, of which safety, effectiveness, accessibility, and affordability are the most. important.
5 Q&A words Do you know that the vaccinated person may still be infected but the condition is mild
More than ten countries have ordered 500 million doses!Global orders for Chinese vaccines exposed
Follow up[China-US wrestling]new situation, immediately understand
Like the fan page of “Hong Kong Economic Times hket.com” immediately
Editor in charge: Lian Zhaofeng
–
